News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oramed Pharmaceuticals Inc. (ORMP.OB) Granted Israeli Patent for Its Core Technology in Oral Delivery of Proteins


5/16/2012 10:08:38 AM

JERUSALEM--(BUSINESS WIRE)--Marking a major milestone for the company, Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Israeli Patent Office. The patent, entitled “Methods and Compositions for Oral Administrations of Proteins,” covers a central facet of the company’s core technology. Oramed’s portfolio now consists of two issued patents and 35 patents pending for its technologies and products.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES